Company / Shareholders' Equity
Catalyst Pharmaceuticals Partners, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$954.3M
FY2025
5-year range
$206.8M / $954.3M
FY2021-FY2025
Trend
+31.1%
vs FY2024
Sector context
#52 of 213
Health Care
What the data says
Catalyst Pharmaceuticals Partners, Inc.'s shareholders' equity of $954M is higher than 76% of companies in the Health Care sector (FY2025). Shareholders' Equity has increased for 8 consecutive years, from $39M in FY2017 to $954M in FY2025.
Based on SEC 10-K filings.
$954M in FY2025 with a 5-year CAGR of +41.3%. Top quartile in the Health Care sector.
Improved from $388M to $954M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +47.0%
- 5-Year CAGR
- +41.3%
- 10-Year CAGR
- -
Sector benchmark
-62.6% below sector average
Key checks
Key Insights
- Catalyst Pharmaceuticals Partners, Inc.'s shareholders' equity has grown for 8 consecutive years.
- 5-year CAGR of +41.3%, indicating consistent growth.
- In FY2025, shareholders' equity increased 31.1% year-over-year.
- Ranks #52 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $954.3M | +31.1% |
| FY2024 | $727.6M | +87.6% |
| FY2023 | $387.9M | +29.1% |
| FY2022 | $300.4M | +45.2% |
| FY2021 | $206.8M | +22.0% |
| FY2020 | $169.6M | +93.5% |
| FY2019 | $87.6M | +72.6% |
| FY2018 | $50.8M | +29.2% |
| FY2017 | $39.3M | +0.0% |
| FY2016 | $39.3M | -29.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026